Tibotec Intelence Not For First-Line Use, FDA Says; Is Follow-On Naive?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The drug interaction profile of Johnson & Johnson subsidiary Tibotec’s antiretroviral Intelence (etravirine) precludes its first-line use against HIV, leaving open a therapeutic niche that Tibotec hopes to fill with another non-nucleoside reverse transcriptase inhibitor, TMC278.
You may also be interested in...
Priority review for Tibotec’s HIV drug etravine
FDA grants priority review to Tibotec's NDA for etravine (TMC125), setting the review clock for a Jan. 18, 2008, user fee date. The non-nucleoside reverse transcriptase inhibitor was the first in the class to show antiviral activity in patients with documented NNRTI resistance, according to the Ortho Biotech subsidiary. The NDA is supported by two Phase III 24-week randomized, double-blinded, placebo-controlled trials - DUET-1 and DUET-2 - that compared the agent in combination with other antiretroviral agents in treatment-experienced HIV-1 patients. TMC125 is currently available through an expanded access program in the U.S., Europe and Canada for HIV-1 infected adults who have experience with each of three major oral classes of ARVs (NRTIs, NNRTIs and protease inhibitors), are unable to use currently approved NNRTIs due to resistance/intolerance and have received at least two PI-based regimens...
Genzyme Receives Complete Response, Warning Letters For Lumizyme
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter
Genzyme Receives Complete Response, Warning Letters For Lumizyme
Despite receiving a “complete response” letter and manufacturing warning letter on the same day, Genzyme remains upbeat about the likelihood of approval for its 2,000L scale-up of Myozyme.